Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Lung Neoplasms 14Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Urinary Bladder Neoplasms 6Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Colorectal Neoplasms 5Melanoma 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Mouth Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoid Interstitial Pneumonia 2Colonic Neoplasms 2

Interventions

Oxaliplatin 16Cetuximab 13Leucovorin 12Fluorouracil 12Bevacizumab 10pembrolizumab 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 6Irinotecan 6Capecitabine 6encorafenib 4Pemetrexed 4Gemcitabine 4Cisplatin 4cemiplimab 3Folfox protocol 3Early Intervention, Educational 3Carboplatin 3Biopsy 3trifluridine tipiracil drug combination 2relatlimab 2pertuzumab 2palbociclib 2fludarabine 2durvalumab 2dehydroftorafur 2aldesleukin 2adagrasib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × Disulfides × 90 days × Clear all
NCT00217737 2026-05-26

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
2,431 enrolled 13 charts
Gastrointestinal

Colonic Neoplasms

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡